Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
1998 Sep
Journal Article
Authors:
Cheson, B.D.;
Sorensen, J.M.;
Vena, D.A.;
Montello, M.J.;
Barrett, J.A.;
Damasio, E.;
Tallman, M.;
Annino, L.;
Connors, J.;
Coiffier, B.;
Lauria, F.
Secondary:
J Clin Oncol
Volume:
16
Pagination:
3007-15
Issue:
9
PMID:
9738569
DOI:
10.1200/JCO.1998.16.9.3007
Keywords:
Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Survival Analysis
Abstract:
PURPOSE: To provide cladribine (CdA) to physicians for the treatment of patients with previously treated or untreated hairy cell leukemia (HCL), and to determine the response rate, response duration, survival, and toxicity with this agent.PATIENTS AND METHODS: This Group C phase II study was open to all eligible patients whose primary physician obtained written permission from the National Cancer Institute (NCI) to register patients onto this protocol. Of 979 patients registered, 861 were assessable for response and 895 for toxicity.RESULTS: The complete remission (CR) rate was 50% and the partial remission (PR) rate was 37%. At a median follow-up of 52 months, 12% of patients were reported to have progressed and 62 (7%) have died of disease.CONCLUSION: This large experience confirms the excellent response rates and remission duration of CdA in patients with HCL. Nevertheless, the response rates in this setting, which approximates general clinical practice, were lower than in other series. In general, CdA was well tolerated, but the potential increased risk for secondary malignancies requires additional follow-up evaluation. CdA can now be considered as one of the best agents for the treatment of HCL.
